New LIGHT Leads The Way To Balance Ischemic And Bleeding Complications Post PCI: Results From The TWILIGHT Trial

Post Percutaneous Coronary Intervention (PCI), dual antiplatelet therapy (DAPT) is recommended for at least a year by various guidelines across the world. However, one must balance the ischemic risk and bleeding risk to achieve the best possible outcomes. Recently presented TWILIGHT trial at TCT 2019 has provided ground-breaking evidence for future antiplatelet strategy post PCI. The current standard of care for patients who have undergone coronary stenting is to combine aspirin with a P2Y 12 inhibitor to prevent the risk of another event.

As per most recent evidence-based guidelines, after PCI with stent placement, preferably including aspirin plus a potent a P2Y 12 inhibitor is recommended for 12 months. 1,2 According to the guidelines given by the  American College of Cardiology, in patients with Acute Coronary Syndrome (ACS) 1. Those who have undergone PCI, and treated with DAPT,…